维泰瑞隆宣布三篇研究成果入选 2025 年美国神经科学年会展示

Core Insights - Vitarylon, a clinical-stage biotechnology company, is focused on developing transformative therapies for age-related diseases and will present three posters at the 2025 Society for Neuroscience Annual Meeting in San Diego from November 15-19, 2025 [1]. Group 1: Poster Presentations - Poster 1: Development of a highly potent, brain-penetrant allosteric RIPK1 inhibitor for the treatment of neurodegenerative diseases, scheduled for November 17, 2025, from 8 AM to 12 PM (Pacific Time) [2]. - Poster 2: Dose-dependent and robust target engagement of a novel brain-penetrant SARM1 inhibitor (SIR2501) in healthy adult participants, scheduled for November 18, 2025, from 8 AM to 12 PM (Pacific Time) [2]. - Poster 3: Discovery of a non-covalent, allosteric SARM1 inhibitor that prevents axonal degeneration in vitro and in vivo, also scheduled for November 18, 2025, from 8 AM to 12 PM (Pacific Time) [2]. Group 2: Company Overview - Vitarylon has been operational since 2017 and is dedicated to discovering and developing breakthrough therapies for age-related degenerative diseases, focusing on key pathogenic mechanisms such as dysregulated cell death, uncontrolled inflammatory responses, and imbalanced energy homeostasis [3]. - The company is currently conducting clinical studies on molecules such as SIR2501, SIR4156, and SIR9900, while also advancing preclinical research efforts [3].